Severe sepsis caused by serious gastrointestinal infection in sJIA patients treated with IL-6 receptor antagonist: a case report

• Egile Nagusiak: Meng Xu (Egilea), Congcong Liu (Egilea), Lishuang Guo (Egilea), Sirui Yang (Egilea)
• Formatua: Liburua
• Argitaratua: BMC, 2020-03-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Abstract Background Interleukin (IL)-6 plays an essential role in the pathogenesis of systemic juvenile idiopathic arthritis (sJIA). Tocilizumab (TCZ), a kind of biological agent against both membrane and soluble IL-6 receptor, is the only biological agent approved for the treatment of sJIA in China...